Symbols

ORGO

Organogenesis·NASDAQ

--(--)

Signals Analysis

Bullish signal 6

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

Revenue Beats Expectation

RSI Oversold

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ORGO

Organogenesis Holdings Inc.

A leading regenerative medicine company that offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics

Industry

Biological Technology

Established Date

Listing Date

12/05/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

854

Fiscal Year Ends

12-31

Website

www.organogenesis.com

Security Type

Common stock

Office address

85 Dan Road , Canton, MA 02021

Business

Introduction

Organogenesis Holdings Inc. is a Delaware corporation. The Company is a leading regenerative medicine company providing a portfolio of bioactive and non-cellular biomaterials in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis' comprehensive product portfolio is designed to treat a variety of patients with repair and regeneration needs.

Company Financials

EPS

ORGO has released its 2025 Q4 earnings. EPS was reported at 0.24, versus the expected 0.22, beating expectations. The chart below visualizes how ORGO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ORGO has released its 2025 Q4 earnings report, with revenue of 225.61M, reflecting a YoY change of 78.13%, and net profit of 43.70M, showing a YoY change of 469.53%. The Sankey diagram below clearly presents ORGO's revenue sources and cost distribution.